Establishment Labs Holdings Inc (ESTA)

$35.8

-1.8

(-4.79%)

Market is closed - opens 8 PM, 22 Feb 2024

Insights on Establishment Labs Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 48.56M → 38.50M (in $), with an average decrease of 20.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -11.94M → -29.27M (in $), with an average decrease of 57.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 43.2% return, outperforming this stock by 89.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 74.1% return, outperforming this stock by 120.7%

Performance

  • $35.69
    $37.32
    $35.80
    downward going graph

    0.31%

    Downside

    Day's Volatility :4.37%

    Upside

    4.07%

    downward going graph
  • $16.96
    $79.88
    $35.80
    downward going graph

    52.63%

    Downside

    52 Weeks Volatility :78.77%

    Upside

    55.18%

    downward going graph

Returns

PeriodEstablishment Labs Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
55.31%
11.8%
0.0%
6 Months
-31.71%
8.6%
0.0%
1 Year
-45.83%
11.4%
-6.3%
3 Years
-44.96%
26.9%
-22.0%

Highlights

Market Capitalization
1.1B
Book Value
$1.18
Earnings Per Share (EPS)
-2.83
Wall Street Target Price
46.14
Profit Margin
-40.32%
Operating Margin TTM
-54.64%
Return On Assets TTM
-15.3%
Return On Equity TTM
-446.93%
Revenue TTM
177.4M
Revenue Per Share TTM
7.03
Quarterly Revenue Growth YOY
0.7000000000000001%
Gross Profit TTM
106.6M
EBITDA
-52.1M
Diluted Eps TTM
-2.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.17
EPS Estimate Next Year
-1.96
EPS Estimate Current Quarter
-0.8
EPS Estimate Next Quarter
-0.58

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Establishment Labs Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 28.88%

Current $35.80
Target $46.14

Company Financials

FY18Y/Y Change
Revenue
61.2M
↑ 76.49%
Net Income
-21.1M
↓ 39.54%
Net Profit Margin
-34.47%
↑ 66.15%
FY19Y/Y Change
Revenue
89.6M
↑ 46.33%
Net Income
-38.2M
↑ 80.82%
Net Profit Margin
-42.59%
↓ 8.12%
FY20Y/Y Change
Revenue
84.7M
↓ 5.46%
Net Income
-38.1M
↓ 0.08%
Net Profit Margin
-45.02%
↓ 2.43%
FY21Y/Y Change
Revenue
126.7M
↑ 49.61%
Net Income
-41.1M
↑ 7.92%
Net Profit Margin
-32.47%
↑ 12.55%
FY22Y/Y Change
Revenue
161.7M
↑ 27.64%
Net Income
-75.2M
↑ 82.82%
Net Profit Margin
-46.51%
↓ 14.04%
FY23Y/Y Change
Revenue
177.4M
↑ 9.71%
Net Income
-71.5M
↓ 4.9%
Net Profit Margin
-40.32%
↑ 6.19%
Q2 FY22Q/Q Change
Revenue
41.2M
↑ 7.12%
Net Income
-37.1M
↑ 525.42%
Net Profit Margin
-90.08%
↓ 74.65%
Q3 FY22Q/Q Change
Revenue
38.2M
↓ 7.15%
Net Income
-18.6M
↓ 49.85%
Net Profit Margin
-48.65%
↑ 41.43%
Q4 FY22Q/Q Change
Revenue
43.8M
↑ 14.56%
Net Income
-13.6M
↓ 27.12%
Net Profit Margin
-30.95%
↑ 17.7%
Q1 FY23Q/Q Change
Revenue
46.5M
↑ 6.19%
Net Income
-11.9M
↓ 11.95%
Net Profit Margin
-25.67%
↑ 5.28%
Q2 FY23Q/Q Change
Revenue
48.6M
↑ 4.38%
Net Income
-16.7M
↑ 40.22%
Net Profit Margin
-34.48%
↓ 8.81%
Q3 FY23Q/Q Change
Revenue
38.5M
↓ 20.71%
Net Income
-29.3M
↑ 74.82%
Net Profit Margin
-76.02%
↓ 41.54%
FY17Y/Y Change
Total Assets
57.1M
↑ 93.14%
Total Liabilities
62.1M
↑ 10.91%
FY18Y/Y Change
Total Assets
116.6M
↑ 104.17%
Total Liabilities
47.1M
↓ 24.18%
FY19Y/Y Change
Total Assets
116.5M
↓ 0.04%
Total Liabilities
76.9M
↑ 63.35%
FY20Y/Y Change
Total Assets
156.4M
↑ 34.2%
Total Liabilities
81.4M
↑ 5.86%
FY21Y/Y Change
Total Assets
139.5M
↓ 10.78%
Total Liabilities
88.8M
↑ 9.04%
FY22Y/Y Change
Total Assets
211.1M
↑ 51.27%
Total Liabilities
219.2M
↑ 146.93%
Q2 FY22Q/Q Change
Total Assets
199.9M
↑ 41.2%
Total Liabilities
184.0M
↑ 96.34%
Q3 FY22Q/Q Change
Total Assets
187.7M
↓ 6.12%
Total Liabilities
186.1M
↑ 1.15%
Q4 FY22Q/Q Change
Total Assets
211.1M
↑ 12.47%
Total Liabilities
219.2M
↑ 17.79%
Q1 FY23Q/Q Change
Total Assets
209.4M
↓ 0.81%
Total Liabilities
225.4M
↑ 2.79%
Q2 FY23Q/Q Change
Total Assets
285.3M
↑ 36.27%
Total Liabilities
230.4M
↑ 2.25%
Q3 FY23Q/Q Change
Total Assets
270.5M
↓ 5.18%
Total Liabilities
240.0M
↑ 4.17%
FY18Y/Y Change
Operating Cash Flow
-33.9M
↑ 5.99%
Investing Cash Flow
-5.7M
↑ 578.22%
Financing Cash Flow
81.5M
↑ 89.63%
FY19Y/Y Change
Operating Cash Flow
-30.0M
↓ 11.52%
Investing Cash Flow
-7.8M
↑ 35.51%
Financing Cash Flow
22.8M
↓ 72.05%
FY20Y/Y Change
Operating Cash Flow
-12.5M
↓ 58.28%
Investing Cash Flow
-5.6M
↓ 28.42%
Financing Cash Flow
64.7M
↑ 183.78%
FY21Y/Y Change
Operating Cash Flow
-27.5M
↑ 120.08%
Investing Cash Flow
-7.2M
↑ 28.85%
Financing Cash Flow
4.1M
↓ 93.73%
FY22Y/Y Change
Operating Cash Flow
-52.2M
↑ 89.47%
Investing Cash Flow
-34.8M
↑ 385.7%
Financing Cash Flow
100.3M
↑ 2374.21%
Q2 FY22Q/Q Change
Operating Cash Flow
-11.3M
↑ 134.09%
Investing Cash Flow
-13.8M
↑ 140.7%
Financing Cash Flow
72.3M
↑ 4166.55%
Q3 FY22Q/Q Change
Operating Cash Flow
-22.0M
↑ 94.0%
Investing Cash Flow
-4.8M
↓ 65.18%
Financing Cash Flow
1.3M
↓ 98.25%
Q4 FY22Q/Q Change
Operating Cash Flow
-14.0M
↓ 36.23%
Investing Cash Flow
-10.4M
↑ 116.8%
Financing Cash Flow
25.0M
↑ 1874.47%
Q1 FY23Q/Q Change
Operating Cash Flow
-20.6M
↑ 47.07%
Investing Cash Flow
-4.3M
↓ 58.98%
Financing Cash Flow
1.2M
↓ 95.26%
Q2 FY23Q/Q Change
Operating Cash Flow
-28.2M
↑ 36.99%
Investing Cash Flow
-9.0M
↑ 111.52%
Financing Cash Flow
84.5M
↑ 7042.18%

Technicals Summary

Sell

Neutral

Buy

Establishment Labs Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc
0.08%
-31.71%
-45.83%
-44.96%
43.51%
Stryker Corporation
Stryker Corporation
11.11%
26.0%
33.25%
43.15%
85.56%
Boston Scientific Corp.
Boston Scientific Corp.
9.02%
31.34%
43.24%
68.93%
65.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
15.62%
13.85%
15.02%
4.27%
49.88%
Abbott Laboratories
Abbott Laboratories
2.15%
12.29%
12.53%
-4.82%
55.23%
Medtronic Plc
Medtronic Plc
-0.72%
5.2%
0.42%
-25.83%
-7.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc
NA
NA
NA
-3.17
-4.47
-0.15
NA
1.18
Stryker Corporation
Stryker Corporation
42.39
42.39
3.23
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
61.51
61.51
2.04
2.25
0.09
0.04
NA
12.89
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.43
37.43
5.26
2.75
0.22
0.11
NA
11.06
Abbott Laboratories
Abbott Laboratories
34.97
34.97
27.54
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
27.41
27.41
1.57
5.16
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc
Buy
$1.1B
43.51%
NA
-40.32%
Stryker Corporation
Stryker Corporation
Buy
$132.8B
85.56%
42.39
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$96.4B
65.05%
61.51
11.19%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.8B
49.88%
37.43
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$197.8B
55.23%
34.97
14.27%
Medtronic Plc
Medtronic Plc
Buy
$112.2B
-7.3%
27.41
12.84%

Institutional Holdings

  • JW Asset Management, LLC

    11.74%
  • RTW INVESTMENTS, LLC

    9.17%
  • Brown Advisory Holdings Inc

    8.93%
  • Nantahala Capital Management, LLC

    6.94%
  • COWEN AND COMPANY, LLC

    4.20%
  • JPMorgan Chase & Co

    3.21%

Corporate Announcements

  • Establishment Labs Holdings Inc Earnings

    Establishment Labs Holdings Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.

Organization
Establishment Labs Holdings Inc
Employees
958
CEO
Mr. Juan Jose Chacon Quiros
Industry
Health Technology

FAQs